TRAW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Traws Pharma Inc (TRAW) is not a good buy for a beginner, long-term investor at this time. The company has weak financial performance, no recent positive news catalysts, and no significant trading or options activity to suggest strong investor sentiment. While the technical indicators show some bullish signs, the lack of AI Stock Picker and SwingMax signals, combined with poor financials, make this stock a hold rather than a buy.
The MACD is positive and contracting, suggesting mild bullish momentum. The RSI is neutral at 39.626, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 1.803, and resistance is at 2.028. However, the stock is trading below the pivot level, indicating limited upside potential in the short term.
Analyst coverage initiated with a Buy rating and a $6.50 price target, indicating potential long-term upside.
No recent news or significant trading trends from hedge funds or insiders. Financial performance is extremely weak, with revenue dropping to zero and significant net income losses in the latest quarter.
In Q3 2025, revenue dropped to $0 (-100% YoY), net income declined to -$3,035,000 (-64.19% YoY), and EPS fell to -0.34 (-96.14% YoY). Gross margin remained at 100%, but this is not indicative of operational strength given the lack of revenue.
Ladenburg initiated coverage with a Buy rating and a $6.50 price target, citing the company's alternative to Cidara's CD388. However, this is the only analyst rating available, limiting the reliability of this sentiment.
